Open-Source Image Analysis Tool Provides Quantitative Assessment of MASH in Mouse Models

As published in Sage Journals, researchers have developed an accessible, machine learning-driven histopathology workflow that enables quantitative evaluation of metabolic dysfunction-associated steatohepatitis (MASH) in laboratory mice without requiring coding expertise…

Continue Reading Open-Source Image Analysis Tool Provides Quantitative Assessment of MASH in Mouse Models

Spatial Mapping Study Uncovers Distinct Molecular Changes Across Liver Regions in MASH

As reported on Bioengineer and ScienMag, a new spatial transcriptomics study has provided fresh insight into how different regions of the liver are remodeled during metabolic dysfunction-associated steatohepatitis (MASH). By…

Continue Reading Spatial Mapping Study Uncovers Distinct Molecular Changes Across Liver Regions in MASH

Wegovy Linked to Normal Liver Fat Levels in Small Analysis of Adults With Obesity

As reported on Medical Daily, small exploratory analysis suggests that semaglutide, the active ingredient in Wegovy, may substantially reduce liver fat in some adults with obesity. However, the findings come…

Continue Reading Wegovy Linked to Normal Liver Fat Levels in Small Analysis of Adults With Obesity

Singapore Approves Wegovy for MASH With Moderate to Advanced Liver Fibrosis

Semaglutide 2.4 mg becomes Singapore’s first approved therapy for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis. As reported on the Manila Times, Singapore’s Health Sciences Authority (HSA) has…

Continue Reading Singapore Approves Wegovy for MASH With Moderate to Advanced Liver Fibrosis

Lean Patients With MASLD Face Higher Risk of Poor Outcomes and Mortality

Key Insight: As reported by Healio, metabolic dysfunction-associated steatotic liver disease (MASLD) is not exclusive to individuals with obesity. New research presented at The Liver Meeting reveals that lean patients…

Continue Reading Lean Patients With MASLD Face Higher Risk of Poor Outcomes and Mortality